Pancreatic Cancer: 18F-Fluorodeoxyglucose Positron Emission Tomography as a Prognostic Parameter

  • Tatsuya Higashi
Part of the Methods of Cancer Diagnosis, Therapy, and Prognosis book series (HAYAT, volume 3)

Patients with pancreatic cancer are known for their poor survival; this caner is the cause of death of ~ 21,100–28,600 patients, and is the sixth and fourth leading cause of cancer death each year in Japan and in the United States, respectively (National Cancer Center, 2001; National Cancer Institute, 1999). At the time of diagnosis after the appearance of symptoms, ~ 80% of patients have an advanced stage that is not suitable for curative operation. The 5-year survival rate of patients with unresectable or metastatic pancreatic cancer is only 0–5%, at the same time the 5-year survival rate of patients who have undergone curative resection is only ~ 10–25%. The incidence of pancreatic cancer in Japan has increased 1.5-fold over the past 3 decades; on the other hand, incidence and mortality rates are identical even now. Although systemic treatment procedures, including operation, chemotherapy, and radiation, are necessary to improve this poor therapeutic outcome, there has been no established treatment method with improved prognosis so far (Oya, 2004).


Positron Emission Tomography Pancreatic Cancer Standardize Uptake Value Creatic Cancer Unresectable Pancreatic Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Armstrong, T., Packham, G., Murphy, L.B., Bateman, A.C., Conti, J.A., Fine, D.R., Johnson, C.D., Benyon, R.C., and Iredale, J.P. 2004. Type I collagen promotes the malignant phenotype of pancreatic ductal adenocarcinoma. Clin. Cancer Res. 10: 7427–7437.PubMedCrossRefGoogle Scholar
  2. Benassai, G., Mastrorilli, M., Moseila, F., and Moseila, G. 1999. Significance of lymph node metastases in the surgical management of pancreatic head carcinoma. J. Exp. Clin. Cancer Res. 18: 23–28.PubMedGoogle Scholar
  3. Beyer, T., Townsend, D.W., and Blodgett, T.M. 2002. Dual-modality PET/CT tomography for clinical oncology. Q. J. Nucl. Med. 46: 24–34.PubMedGoogle Scholar
  4. Demeure, M.J., Doffek, K.M., Komorowski, R.A., and Wilson, S.D. 1998. Adenocarcinoma of the pancreas: detection of occult metastases in regional lymph nodes by a polymerase chain reaction-based assay. Cancer 83: 1328–1334.PubMedCrossRefGoogle Scholar
  5. Franke, C., Klapdor, R., Meyerhoff, K., and Schauman, M. 1999. 18-FDG positron emission tomography of the pancreas: diagnostic benefit in the follow-up of pancreatic carcinoma. Anticancer Res. 19: 2437–2442.PubMedGoogle Scholar
  6. Frohlich, A., Diederichs, C.G., Staib, L., Vogel, J., Beger, H.G., and Reske, S.N. 1999. Detection of liver metastases from pancreatic cancer using FDG PET. J. Nucl. Med. 40: 250–255.PubMedGoogle Scholar
  7. Fujino, Y., Suzuki, Y., Ajiki, T., Ku, Y., and Kuroda, Y. 2003. Predicting factors for survival of patients with unresectable pancreatic cancer: a management guideline. Hepatogastroenterology 50: 250–253.PubMedGoogle Scholar
  8. Fukunaga, A., Miyamoto, M., Cho, Y., Murakami, S., Kawarada, Y., Oshikiri, T., Kato, K., Kurokawa, T., Suzuoki, M., Nakakubo, Y., Hiraoka, K., Itoh, T., Morikawa, T., Okushiba, S., Kondo, S., and Katoh, H. 2004. CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas 28: e26–e31.PubMedCrossRefGoogle Scholar
  9. Gebhardt, C., Meyer, W., Reichel, M., and Wunsch, P.H. 2000. Prognostic factors in the operative treatment of ductal pancreatic carcinoma. Langenbecks Arch. Surg. 385: 14–20.PubMedCrossRefGoogle Scholar
  10. Hartel, M., DiMola, F.F, Gardini, A., Zimmermann, A., Di Sebastiano, P., Guweidhi, A., Innocenti, P., Giese, T., Giese, N., Buchler, M.W., and Friess, H. 2004. Desmoplastic eaction influences pancreatic cancer growth behavior. World J. Surg. 28: 818–825.PubMedCrossRefGoogle Scholar
  11. Heinrich, S., Goerres, G.W., Schafer, M., Sagmeister, M., Bauerfeind, P., Pestalozzi, B.C., Hany, T.F., von Schulthess, G.K., and Clavien, P.A. 2005. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann. Surg. 242: 235–243.PubMedCrossRefGoogle Scholar
  12. Hicks, R.J., Kalff, V., MacManus, M.P., Ware, R.E., Hogg, A., McKenzie, A.F., Matthews, J.P., and Ball, D.L. 2001. (18)F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J. Nucl. Med. 42: 1596–1604.PubMedGoogle Scholar
  13. Higashi, K., Ueda, Y., Arisaka, Y., Sakuma, T., Nambu, Y., Oguchi, M., Seki, H., Taki, S., Tonami, H., and Yamamoto, I. 2002. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J. Nucl. Med. 43: 39–45.PubMedGoogle Scholar
  14. Higashi, T., Tamaki, N., Honda, T., Torizuka, T., Kimura, T., Inokuma, T., Ohshio, G., Hosotani, R., Imamura, M., and Konishi, J. 1997. Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. J. Nucl. Med. 38: 1337–1344.PubMedGoogle Scholar
  15. Higashi, T., Tamaki, N., Torizuka, T., Nakamoto, Y., Sakahara, H., Kimura, T., Honda, T., Inokuma, T., Katsushima, S., Ohshio, G., Imamura, M., and Konishi, J. 1998. FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors. J. Nucl. Med. 39: 1727–1735.PubMedGoogle Scholar
  16. Higashi, T., Sakahara, H., Torizuka, T., Nakamoto, Y., Kanamori, S., Hiraoka, M., Imamura, M., Nishimura, Y., Tamaki, N., and Konishi, J. 1999. Evaluation of intraoperative radiation therapy for unresectable pancreatic cancer with FDG PET. J. Nucl. Med. 40: 1424–1433.PubMedGoogle Scholar
  17. Higashi, T., Saga, T., Nakamoto, Y., Ishimori, T., Mamede, M.H., Wada, M., Doi, R., Hosotani, R., Imamura, M., and Konishi, J. 2002. Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J. Nucl. Med. 43: 173–180.PubMedGoogle Scholar
  18. Higashi, T., Saga, T., Nakamoto, Y., Ishimori, T., Fujimoto, K., Doi, R., Imamura, M., and Konishi, J. 2003. Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET)-usefulness and limitations in “clinical reality”. Ann. Nucl. Med. 17: 261–279.PubMedCrossRefGoogle Scholar
  19. Ito, H., Duxbury, M., Zinner, M.J., Ashley, S.W., and Whang, E.E. 2004. Glucose transporter-1 gene expression is associated with pancreatic cancer invasiveness and MMP-2 activity. Surgery 136: 548–556.PubMedCrossRefGoogle Scholar
  20. Jeong, H.J., Min, J.J., Park, J.M., Chung, J.K., Kim, B.T., Jeong, J.M., Lee, D.S., Lee, M.C., Han, S.K., and Shim, Y.S. 2002. Determination of the prognostic value of [(18)F]fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer. Nucl. Med. Commun. 23: 865–870.PubMedCrossRefGoogle Scholar
  21. Keyes, J.W. Jr. 1995. SUV: standard uptake or silly useless value? J. Nucl. Med. 36: 1836–1839.PubMedGoogle Scholar
  22. Klinkenbijl, J.H., Jeekel, J., Sahmoud, T., van Pel, R., Couvreur, M.L., Veenhof, C.H., Arnaud, J.P., Gonzalez, D.G., de Wit, L.T., Hennipman, A., and Wils, J. 1999. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann. Surg. 230: 776–782.PubMedCrossRefGoogle Scholar
  23. Kuhlmann, K.F., de Castro, S.M., Wesseling, J.G., ten Kate, F.J., Offerhaus, G.J., Busch, O.R., van Gulik, T.M., Obertop, H., and Gouma, D.J. 2004. Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients. Eut J. Cancer 40: 549–558.CrossRefGoogle Scholar
  24. Lemke, A.J., Niehues, S.M., Hosten, N., Amthauer, H., Boehmig, M., Stroszczynski, C., Rohlfing, T., Rosewicz, S., and Felix, R. 2004. Retrospective digital image fusion of multidetector CT and 18F-FDG PET: clinical value in pancreatic lesions-a prospective study with 104 patients. J. Nucl. Med. 45: 1279–1286.PubMedGoogle Scholar
  25. Lim, J.E., Chien, M.W., and Earle, C.C. 2003. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann. Surg. 237: 74–85.PubMedCrossRefGoogle Scholar
  26. Louvet, C., Labianca, R., Hammel, P., Lledo, G., Zampino, M.G., Andre, T., Zaniboni, A., Ducreux, M., Aitini, E., Taieb, J., Faroux, R., Lepere, C., and de Gramont, A.; GERCOR; GISCAD. 2005. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J. Clin. Oncol. 23: 3509–3516.PubMedCrossRefGoogle Scholar
  27. Lyshchik, A., Higashi, T., Nakamoto, Y., Fujimoto, K., Doi, R., Imamura, M., and Saga, T. 2005. Dual-phase 18F-fluoro-2-deoxy-D-glucose positron emission tomography as a prognostic parameter in patients with pancreatic cancer. Eur. J. Nucl. Med. Mol. Imaging. 32: 389–397.PubMedCrossRefGoogle Scholar
  28. Lyshchik, A., Higashi, T., Hara, T., Nakamoto, Y., Fujimoto, K., Doi, R., Imamura, M., Saga, T., and Togashi, K. 2007. Expression of glucose transporter-1, hexokinase, proliferating nuclear antigen and survival of the patients with pancreatic cancer. Cancer Invest. 25: 154–162.PubMedCrossRefGoogle Scholar
  29. Maisey, N.R., Webb, A., Flux, G.D., Padhani, A., Cunningham, D.C., Ott, R.J., and Norman, A. 2000. FDG-PET in the prediction of survival of patients with cancer of the pancreas: a pilot study. Br. J, Cancer. 83: 287–293.CrossRefGoogle Scholar
  30. McNulty, N.J., Francis, I.R., Platt, J.F., Cohan, R.H., Korobkin, M., and Gebremariam, A. 2001. Multi-detector row helical CT of the pancreas: effect of contrast-enhanced multiphasic imaging on enhancement of the pancreas, peripancreatic vasculature, and pancreatic adenocarcinoma. Radiology 220: 97–102.PubMedGoogle Scholar
  31. Minn, H., Lapela, M., Klemi, P.J., Grenman, R., Leskinen, S., Lindholm, P., Bergman, J., Eronen, E., Haaparanta, M., and Joensuu, H. 1997. Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. J. Nucl. Med. 38: 1907–1911.PubMedGoogle Scholar
  32. Morganti, A.G., Brizi, M.G., Macchia, G., Sallustio, G., Costamagna, G., Alfieri, S., Mattiucci, G.C., Valentini, V., Natale, L., Deodato, F., Mutignani, M., Doglietto, G.B., and Cellini, N. 2005. The prognostic effect of clinical staging in pancreatic adenocarcinoma. Ann. Surg. Oncol. 12: 145–151.PubMedCrossRefGoogle Scholar
  33. Nakamoto, Y., Higashi, T., Sakahara, H., Tamaki, N., Kogire, M., Imamura, M., and Konishi, J. 1999. Contribution of PET in the detection of liver metastases from pancreatic tumours. Clin. Radiol. 54: 248–252.PubMedCrossRefGoogle Scholar
  34. Nakata, B., Chung, Y.S., Nishimura, S., Nishihara, T., Sakurai, Y., Sawada, T., Okamura, T., Kawabe, J., Ochi, H., and Sowa, M. 1997. 18F-fluorodeoxy-glucose positron emission tomography and the prognosis of patients with pancreatic adenocarcinoma. Cancer 79: 695–699.PubMedCrossRefGoogle Scholar
  35. Nakata, B., Nishimura, S., Ishikawa, T., Ohira, M., Nishino, H., Kawabe, J., Ochi, H., and Hirakawa, K. 2001. Prognostic predictive value of 18F-fluorodeoxyglucose positron emission tomography for patients with pancreatic cancer. Int. J. Oncol. 19: 53–58.PubMedGoogle Scholar
  36. National Cancer Center. 2001. The 2001 edition of Cancer Statistics in Japan.
  37. National Cancer Institute. 1999. SEER cancer statistics review 1973–1996. NIH Publication No. 99-2789. Bethesda, Department of Health and Human Services.Google Scholar
  38. Neoptolemos, J.P., Stocken, D.D., Friess, H., Bassi, C., Dunn, J.A., Hickey, H., Beger, H., Fernandez-Cruz, L., Dervenis, C., Lacaine, F., Falconi, M., Pederzoli, P., Pap, A., Spooner, D., Kerr, D.J., and Buchler, M.W.; European Study Group for Pancreatic Cancer. 2004. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N. Engl. J. Med. 350: 1200–1210.PubMedCrossRefGoogle Scholar
  39. Oya, N. 2004. Chemoradiotherapy for pancreatic cancer: current status and perspectives. Int. J. Clin. Oncol. 9: 451–457.PubMedCrossRefGoogle Scholar
  40. Prokesch, R.W., Chow, L.C., Beaulieu, C.F., Bammer, R., and Jeffrey, R.B. Jr. 2002a. Isoattenuating pancreatic adenocarcinoma at multi-detector row CT: secondary signs. Radiology 224: 764–768.PubMedCrossRefGoogle Scholar
  41. Prokesch, R.W., Chow, L.C., Beaulieu, C.F., Nino-Murcia, M., Mindelzun, R.E., Bammer, R., Huang, J., and Jeffrey, R.B. Jr. 2002b. Local staging of pancreatic carcinoma with multi-detector row CT: use of curved planar reformations initial experience. Radiology 225: 759–765.PubMedCrossRefGoogle Scholar
  42. Sperti, C., Pasquali, C., Chierichetti, F., Ferronato, A., Decet, G., and Pedrazzoli, S. 2003. 18-Fluorodeoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma. J. Gastrointest. Surg. 7: 953–959.PubMedCrossRefGoogle Scholar
  43. Stojadinovic, A., Brooks, A., Hoos, A., Jaques, D.R, Conlon, K.C., and Brennan, M.F. 2003. An evidence-based approach to the surgical management of resectable pancreatic adenocarcinoma. J. Am. Coll. Surg. 196: 954–964.PubMedCrossRefGoogle Scholar
  44. Weber, W.A. 2005. Use of PET for monitoring cancer therapy and for predicting outcome. J. Nucl. Med. 46: 983–995.PubMedGoogle Scholar
  45. Zimny, M., Bares, R., Fass, J., Adam, G., Cremerius, U., Dohmen, B., Klever, P., Sabri, O., Schumpelick, V., and Buell, U. 1997. Fluorine-18 fluorodeoxyglucose positron tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. Eut J. Nucl. Med. 24: 678–682.Google Scholar
  46. Zimny, M., Fass, J., Bares, R., Cremerius, U., Sabri, O., Buechin, P., Schumpelick, V., and Buell, U. 2000. Fluorodeoxyglucose positron emission tomography and the prognosis of pancreatic carcinoma. Scand. J. Gastroenterol. 35: 883–888.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media B.V. 2008

Authors and Affiliations

  • Tatsuya Higashi
    • 1
  1. 1.Department of Nuclear Medicine and Diagnostic ImagingKyoto University Graduate School of MedicineKyotoJapan

Personalised recommendations